New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
10:19 EDTEGRXEagle Pharmaceuticals IPO indicated to open $15.50
Eagle Pharmaceuticals (EGRX) priced 3.35M shares at $15.00. Piper Jaffray and William Blair acted as joint book running managers for the offering.
News For EGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2015
11:05 EDTEGRXEagle Pharmaceuticals price target raised to $65 from $51 at Cantor
Subscribe for More Information
08:03 EDTEGRXTeva, Eagle announce NDA for bendamustine HCI accepted for filing
Subscribe for More Information
April 13, 2015
13:25 EDTEGRXEagle Pharmaceuticals appoints Fibrocell CEO to board of directors
Subscribe for More Information
April 7, 2015
10:51 EDTEGRXEagle Pharmaceuticals announces new patent for low-sodium bendamustine
Eagle Pharmaceuticals announced that the United States Patent and Trademark Office has granted Patent No. 9,000,021 for the use of bendamustine for treating patients requiring restricted fluid and/or sodium intake. The patent issued today expires in March 2033. On February 13, 2015, Eagle submitted a New Drug Application to the FDA for bendamustine hydrochloride for administration in a 50mL admixture for the treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Eagle has requested Priority Review of the NDA; this product candidate has received Orphan Drug Designations for both CLL and indolent B-cell NHL, and therefore may be eligible for seven years of exclusivity upon approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use